|Bid||0.00 x 1000|
|Ask||0.00 x 1400|
|Day's range||29.90 - 31.07|
|52-week range||15.72 - 146.16|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||13 Dec 2012|
|1y target est||N/A|
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $30.44, marking a -1.17% move from the previous day.
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $26.43, marking a -1.38% move from the previous day.
Cassava Sciences, Inc.'s (NASDAQ:SAVA) a clinical stage biotechnology company, is developing a drug for Alzheimer - a neurodegenerative disease, affecting more than 35.7 million people worldwide (6 million in the US). In this article, we will review Cassava's product line and cash capacity to fund further research until FDA approval.